Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELEPIK: Decentralized trial of Alpelisib in breast cancer
NCT04862143Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alpelisib in breast cancer, sponsored by Novartis. Primary endpoint: Participant Satisfaction Assessed Through the Trial Feedback Questionnaire (TFQ). Started Mar 2022; status: terminated.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04862143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04862143.